Product Datasheet
|
Catalog Number |
ATCS1130 |
|
Product Name |
HEPG2 |
|
Species |
Homo sapiens (Human) |
|
Source |
Established from the tumor tissue of a 15-year-old boy in 1975 (originally described as a hepatocellular carcinoma but others suggest it as a hepatoblastoma); cell line was patented in 1980; cells were described in the literature to not harbor a hepatitis B virus genome; cells reportedly produce a variety of proteins: alpha-fetoprotein, albumin, alpha2-macroglobulin, alpha1-antiTrypsin, transferrin, alpha1-antichymoTrypsin, haptoglobin, ceruloplasmin, plasminogen, complement (C3, C4), C3 activator, fibrinogen, alpha1-acid glycoprotein, alpha2-HS glycoprotein, ß-lipoprotein, retinol binding protein. |
|
Type |
Hepatoma |
|
Morphology |
Epithelial |
|
Culture Medium |
80-90% RPMI-1640 + 10-20% FBS |
|
Subculture |
Seed out at about 2-3 x 10^6 cells/80 cm²; Split confluent culture 1:2 to 1:4 every 3-6 days using Trypsin/EDTA. |
|
Split Ratio |
1:2 to 1:4 |
|
Doubling Time |
50-60 h |
|
Incubation |
Incubate the cells at 37 °C with 5% CO2. |
|
Frozen Medium |
90% culture medium + 10% DMSO |
|
Biosafety Level |
1 |
|
Size |
1 vial |
|
Quantity |
>5×10^5 cells per vial |
|
Protocol |
|
|
Storage |
Vapor phase of liquid nitrogen |
|
Shipping Condition |
The cancer cell lines are shipped out in dry ice. |
|
Note |
This product is for research use only. |
.jpg){kind=logo}
